Des Rosiers C. Circulating acylcarnitine profile in human heart failure: a surrogate of fatty acid metabolic dysregulation in mitochondria and beyond. Am J Physiol Heart Circ Physiol 313: H768 -H781, 2017. First published July 14, 2017; doi:10.1152/ajpheart.00820. 2016.-Heart failure (HF) is associated with metabolic perturbations, particularly of fatty acids (FAs), which remain to be better understood in humans. This study aimed at testing the hypothesis that HF patients with reduced ejection fraction display systemic perturbations in levels of energy-related metabolites, especially those reflecting dysregulation of FA metabolism, namely, acylcarnitines (ACs). Circulating metabolites were assessed using mass spectrometry (MS)-based methods in two cohorts. The main cohort consisted of 72 control subjects and 68 HF patients exhibiting depressed left ventricular ejection fraction (25.9 Ϯ 6.9%) and mostly of ischemic etiology with Ն2 comorbidities. HF patients displayed marginal changes in plasma levels of tricarboxylic acid cycle-related metabolites or indexes of mitochondrial or cytosolic redox status. They had, however, 22-79% higher circulating ACs, irrespective of chain length (P Ͻ 0.0001, adjusted for sex, age, renal function, and insulin resistance, determined by shotgun MS/MS), which reflects defective mitochondrial ␤-oxidation, and were significantly associated with levels of NH 2-terminal pro-B-type natriuretic peptide levels, a disease severity marker. Subsequent extended liquid chromatography-tandem MS analysis of 53 plasma ACs in a subset group from the primary cohort confirmed and further substantiated with a comprehensive lipidomic analysis in a validation cohort revealed in HF patients a more complex circulating AC profile. The latter included dicarboxylic-ACs and dihydroxy-ACs as well as very long chain (VLC) ACs or sphingolipids with VLCFAs (Ͼ20 carbons), which are proxies of dysregulated FA metabolism in peroxisomes. Our study identified alterations in circulating ACs in HF patients that are independent of biological traits and associated with disease severity markers. These alterations reflect dysfunctional FA metabolism in mitochondria but also beyond, namely, in peroxisomes, suggesting a novel mechanism contributing to global lipid perturbations in human HF.
DESPITE effective evidence-based therapies, heart failure (HF) remains a common debilitating illness affecting up to 3% of the worldwide population with increasing prevalence (22) . HF is a complex and multifactorial condition (22) and heterogeneous with respect to biological traits, namely, sex, age, comorbidities, as well as etiologies (20) . The associated high rate of mortality continues to provide an impetus for searching new therapeutic targets (12, 26, 72) . In this regard, energy substrate metabolism is being intensively investigated. Although evidence supports the energy-starvation hypothesis of the failing heart (5, 64) , there are, however, some controversies in the field, particularly with respect to fatty acid (FA) metabolic alterations as well as the potential benefit of their modulation in human HF. The repeated demonstration of abnormalities in cardiac FA uptake and oxidation in most studies from animal models and human subjects (56) have led to the hypothesis that free FAs (FFAs) are detrimental, whereas partial inhibition of FA oxidation would be beneficial (41) . Unexpectedly, however, acute systemic depletion of FFAs in nondiabetic human HF caused by idiopathic dilated cardiomyopathy paradoxically depressed cardiac work (63) . The impact of HF, however, goes beyond the heart, being characterized by multiple organ dysfunctions, which contribute to disease severity or comorbidities such as insulin resistance, muscle weakness, and chronic renal failure, and to global metabolic disturbances and, conversely, may be affected by any given interventions (52, 68) . Clearly, much remains to be learned about the impact of human HF on energy substrate metabolism as a whole, particularly FAs, and their association with disease severity and comorbidities.
The use of recently emerging metabolomic technologies has provided some novel insight into the global metabolic perturbations prevailing in several cardiovascular diseases (62) . Specifically, using both targeted and untargeted approaches in blood samples, a few studies have highlighted a metabolic signature, which reflected, for example, metabolic "feminization" (i.e., androgen metabolites are decreased) in men with primary dilated cardiomyopathy (3) , an increased ketone body utilization in severe HF (10) , and a distinction between HF patients with reduced versus preserved ejection fraction (73) , although they also shared similar FA metabolic perturbations as highlighted by increased long-chain acylcarnitines (LCACs), reflecting defective mitochondrial ␤-oxidation (33) . There are, however, a number of issues that remain to be clarified in HF, namely, as to whether there are specific alterations in oxidation of substrates, specifically FAs, in mitochondria but also beyond, in other organelles such as peroxisomes, irrespective of confounding factors such as age, sex, etiology, or comorbidities.
Profiling of circulating acylcarnitines (ACs) has commonly been used for the diagnosis of inborn errors of metabolism, particularly mitochondrial FA oxidation defects (47) . Intracellular AC formation is recognized as a mechanism to buffer potentially toxic acyl-CoA metabolites accumulating in cells under conditions such as impaired mitochondrial FA oxidation (44) to maintain optimal activity of mitochondrial tricarboxylic acid (TCA) cycle-related enzymes. In contrast to acyl-CoAs, which remain sequestered in mitochondria, ACs can be transported out of mitochondria and out of the cell to the bloodstream and thereby directly reflect the intracellular pool of corresponding acyl-CoAs (24, 59) . It is noteworthy that although FA ␤-oxidation in mitochondria is directly coupled to ATP production, this is not the case of other organelles that are metabolically connected to mitochondria such as peroxisomes, which oxidize more complex lipids such as very long chain (VLC) or dicarboxylic (DC) FAs (70) . In this regard, although mitochondrial FA ␤-oxidation dysfunction is accepted in HF, to the best of our knowledge, the contribution of other organelles related to FA oxidation in HF remains to be examined.
Hence, in this study, we tested the hypothesis that HF patients with reduced ejection fraction display systemic perturbations in levels of energy-related metabolites, particularly ACs, reflecting dysregulation of FA metabolism in mitochondria and beyond in peroxisomes. For this, we applied targeted mass spectrometry (MS)-based metabolomics as well as a more comprehensive lipid profiling using liquid chromatographytandem MS (LC-MS/MS) analysis in control and HF subjects from two independent cohorts.
METHODS

Subjects and Sample Collection
Blood samples were collected in EDTA tube on ice from two different patient cohorts after an overnight fast and rapidly centrifuged. Plasma was immediately frozen in separate aliquots and kept at Ϫ80°C until assayed. All analyses were performed on frozen plasma aliquots that had not been previously unthawed.
Primary cohort. Subjects were recruited at the Montreal Heart Institute (MHI). For this cohort, which has been described in a previous publication, blood sample was drawn from an antecubital vein (6) . The present study reports data for 140 subjects, namely, 68 symptomatic HF patients receiving evidence-based therapy and 72 control subjects for which all measured parameters were recalculated. The study protocol was approved by the MHI research ethics committee, and all subjects had given their written informed consent.
Validation cohort. Subjects were recruited at Washington University. For this second cohort, which has also been previously described (34), we had access to plasma samples from the central vein (CV) for 8 control subjects and 8 HF patients and coronary sinus (CS) for 8 control subjects and 10 HF patients with reduced ejection fraction. The study protocol was approved by the Washington University Human Research Protection Office, and all subjects had given their written informed consent.
Clinical Biochemical Determinations and Metabolite Profiling
Standard parameters. The following parameters were measured in plasma samples as previously described (6): glucose, urea, creatinine, uric acid, FFA-cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, NH 2-terminal pro-B-type natriuretic peptide (NT-ProBNP), troponin T, insulin, TNF-␣, alanine aminotransferase (ALT), asparagine aminotransferase (AST), total bilirubin, alkaline phosphatase, and C-reactive protein. The estimated glomerular filtration rate (eGFR) and homeostatic model assessment of insulin resistance (HOMA-IR) were calculated by the Cockcroft and Gault (14) and Matthews (43) formulas, respectively.
Energy-related metabolites. Plasma levels of lactate, pyruvate, ketone bodies including acetoacetate and ␤-hydroxybutyrate, glycerol, and TCA cycle intermediates (citrate, succinate, fumarate, and malate) were quantified by isotope dilution gas chromotography-MS as previously described (60) . Lactate-to-pyruvate and ␤-hydroxybutyrate-to-acetoacetate ratios were used as proxies for cytosolic or mitochondrial redox state, respectively (18) .
Acylcarnitines. In the text, Cx refers to the number of carbons in the acyl chain of carnitine derivatives (for example, if x ϭ 2, it refers to 2 carbons in the acyl chain), and the various classes of ACs are referred to as follows: 1) acetylcarnitine (C2) and short-chain ACs (SCACs: C3ϩC4ϩC5), 2) medium-chain ACs (MCACs: C6ϩC8ϩ C10ϩC12), 3) long-chain ACs (LCACs: C14ϩC16ϩC18) ACs, 4) hydroxylated ACs (OH-ACs), and 5) DC-ACs. Isomers of the same AC species, whose structure remains to be elucidated, are indicated using numbers (e.g., AC #1/#2).
SHOTGUN MS/MS. Plasma and blood levels of free carnitine and 13 ACs were first analyzed after a routine procedure for screening of inherited FA oxidation defects using deuterated AC standards (obtained from Dr. H Ten Brink, VU Medical Center, Metabolic Laboratory, Amsterdam, The Netherlands). Briefly, plasma and blood samples were analyzed by electrospray ionization (ESI) MS-MS (Appleura API 3000 triple quadrupole tandem MS equipped with an ion spray source, Applied Biosystems/MSD SCIEX) without chromatographic separation. Levels of free carnitine (C0) and of saturated ACs (C2 to C18) in 20-l plasma samples were quantified after a multiple reaction monitoring method using [
2 H3]methyl-carnitine and standard curves and are expressed in micromolars. AC profiles, which include saturated and some unsaturated of various chain lengths, were also assessed using a semiquantitative method in blood samples spotted on a Guthrie card. Eluted samples were spiked with deuterated acylcarnitine standards ([  2 H3 ]acetyl-carnitine, [ 2 H3]octanoyl-carnitine, and [
2 H3]octadecanoyl-carnitine) and analyzed by a positive precursor ion scan of m/z 99 (scan range m/z: 200 -500). In blood samples, measured levels of the different classes of ACs, namely, 1) acetylcarnitine and SCACs, 2) MCACs, and 3) LCACs, are reported as ratios and expressed relative to levels of corresponding deuterated standards. It is important to note that with this approach, signals for OH-ACs, DC-ACs, and unsaturated ACs were not detected both in HF patients and control subjects except for C18:1-and C18:2-carnitine in blood samples. Consequently, we only reported results in blood samples, although results were similar in blood and plasma with a strong and significant correlation for all species (Pearson r Ͼ 0.4, P Ͻ 0.0001, data not shown).
LC-MS/MS. Extended profiling of 53 ACs using LC-MS/MS [HPLC with an Atlantis dC18 column (50 ϫ 4.6 mm, particle size: 3 M, Waters) coupled to a 6460 triple quadrupole MS/MS system equipped with an electrospray ionization jet stream source; Agilent Technologies] was achieved as previously described (49) . This is a semiquantitative method based on the use of labeled internal standards for seven different ACs. AC species analyzed, retention times, internal standards used for normalization, and within coefficient of variation values (in %) based on five separate extractions analyzed on the same day are reported in the Supplemental Material (Excel Sheet S1; Supplemental Material for this article is available at the American Journal of Physiology-Heart and Circulatory Physiology website).
Lipid profiling using LC-MS/MS analysis. Procedures for lipid extraction and analysis were essentially as previously described (19, 35) . In brief, lipids were extracted from plasma (100 l), which had been spiked with six internal standards, and samples were injected through a dual electrospray ion source onto a 1290 Infinity HPLC coupled with a 6530 Accurate Mass quadrupole-time of flight (Q-TOF) (Agilent Technologies). Lipids elution was assessed on a Zorbax Eclipse plus C18 column (2.1 ϫ 100 mm, particles size: 1.8 m, Agilent Technologies) at 40°C and analyzed both in positive and negative mode. All detected MS features are characterized by a specific mass (m/z) and retention time. Those that discriminated HF patients from control subjects were selected according to the following criteria: 1.3-fold change and P value Ͻ 0.01 using an unpaired t-test, before identification by database (METLIN) search followed by tandem MS analysis to identify lipid species as well as fatty acyl chain composition and side chain positions (sn1 and sn2) (31) . We also had a specific focus on lipid species containing VLCFA derivatives, as a surrogate of impaired peroxisomal metabolism, such as C26-ACs (65) or sphingolipids containing VLCFAs as acyl side chains (51) .
Statistical Analysis
Patient characteristics are expressed as means Ϯ SD, median (minimum-maximum), or frequencies and percentages depending on the distribution of data. A logarithmic transformation was used for continuous variables that exhibited a severely skewed distribution. Univariate statistical analyses were performed with Software SAS version 8.2 or Graph Pad Prism version 5. Because of significant differences in age and sex between control and HF subjects, comparisons between these two groups for clinical and biochemical characteristics were conducted using analysis of covariance (ANCOVA) adjusting for sex and age as covariates. Comparisons between the two groups for all metabolites measured were adjusted for 1) sex and age; 2) sex, age, and insulin resistance (HOMA-IR); and 3) sex, age, HOMA-IR, and renal function (eGFR) as covariates. We adjusted for the last two factors since they were significantly different between control and HF subjects and are known to affect plasma metabolite levels and ACs in particular (25, 54) . Categorical variables such as New York Heart Association (NYHA) classes and type 2 diabetes (T2D) were analyzed by Pearson 2 -test, and continuous variables were analyzed using t-test (for symmetric distribution) or Wilcoxon sign rank test (for asymmetric distribution). All measured parameters (clinical, biochemical, and metabolites) were submitted to exploratory unsupervised multivariate principal component analysis (PCA) to assess their capacity to discriminate HF patients from control subjects (SIMCA, version 13.0, Umetrics). Subsequently, unadjusted Pearson's correlation analysis was used to test for associations between metabolites having the highest loading scores in the PCA and therefore contributed the most to the Data are means Ϯ SD or medians (minimum Ϫ maximum). HF, heart failure; NYHA, New York Heart Association; NT-ProBNP, NH2-terminal pro-B-type natriuretic peptide; eGFR, estimated glomerular filtration rate; HOMA-IR, homeostatic model assessment of insulin resistance; NS, not significant. *P values, HF patients vs. control subjects using covariance analysis adjusting for age and sex as covariates; †P values, nondiabetic vs. diabetic HF patients; ‡P values, NYHA class II vs. class III for HF patients; §parameter exhibiting a severely skewed distribution and for which a logarithmic transformation was used. separation between the groups, and markers of HF severity. For extended AC analysis in a subgroup of the primary cohort and the replication cohort, we used a t-test with Benjamini-Hochberg correction for multiple comparisons; a false discovery rate (FDR) of 10% was applied, and the results are depicted as a volcano plot (Mass Profiler Professional software version 12.6.1, Agilent Technologies). Tables 1 and 2 show clinical and biochemical characteristics of the primary cohort of this study, which were similar to those previously reported (6) . In this study, we include results from covariance analysis testing the impact of the NYHA class and diabetes. In brief, HF patients displayed markedly depressed left ventricular ejection fraction (mean: 25.9 Ϯ 6.9%). They were roughly equally distributed between NYHA class II (41%) and III (56%), mostly of ischemic etiology (63%). Most of them presented two or more comorbidities, including T2D (46%) and hypertension (47%), and as per guidelines they receive multiple medications compared with controls, which included diuretics (93%), renin-angiotensin system inhibitors (82%), ␤-blockers (78%), lipid-lowering agents (72%), and salicylates (53%). Compared with control subjects, they also exhibited marked perturbations in routinely measured plasma biochemical and hormonal parameters, as shown in Table 3 , including increased NT-ProBNP (46-fold), creatinine (1.9-fold, reflecting renal dysfunction, consistent with the 36% decreased eGFR), urea (2-fold), triglycerides (1.5-fold), glucose (1.5-fold), insulin (1.5-fold), as well as HOMA-IR scores (2.4-fold, reflecting insulin resistance). Finally, HF patients were also characterized by significant elevation in other plasma parameters, including C-reactive protein (3.7-fold) and alkaline phosphatase (1.5-fold), but specific markers of liver function were unchanged, namely, ALT, AST, and total bilirubin. Among HF patients, none of these parameters differed significantly between NYHA classes II versus III (3 patients were class I), and only a few of them differed significantly between nondiabetic and diabetic patients (body mass index, systolic and diastolic blood pressure, hypoglycemic agents, total cholesterol, glucose, or HOMA-IR), as highlighted by covariance analysis.
RESULTS
Characteristics of the Primary Cohort
HF Patients Display Marked Alterations in Circulating Levels of ACs But Marginal Changes in Other Energy-Related Metabolites
Plasma concentrations of energy-related metabolites, namely, TCA cycle intermediates and amino acids as well as proxies of Fig. 1 . Shotgun MS/MS analysis of acylcarnitine species between heart failure (HF) patients and control subjects in the primary cohort. Circulating levels for the 14 acylcarnitines assessed in HF patients (gray, n ϭ 72) and controls (white, n ϭ 68) (A) and in HF patients without (white, n ϭ 37) or with diabetes (gray, n ϭ 31) (B) are shown as box plots with rectangles displaying SD, the segment inside the median, and "whiskers" above and below the minimum and maximum. *P Ͻ 0.05, **P Ͻ 0.01, and ***P Ͻ 0.001, HF patients vs. control subjects using analysis of covariance after adjusting for age, sex, homeostatic model assessment of insulin resistance (HOMA-IR), and estimated glomerular filtration rate (eGFR) as covariates; $$P Ͻ 0.01, effect of diabetes; ##P Ͻ 0.01, nondiabetic vs. diabetic HF.
cytosolic and mitochondrial redox status, are shown in Table 3 along with 1) P values adjusted for age and sex; 2) age, sex, and HOMA-IR; and 3) age, sex, HOMA-IR, and eGFR, as well as P values for the effect of diabetes. There were no significant differences between the two groups after adjusting for age, sex, HOMA-IR, and eGFR except for citrate and phenylalanine, which remained significantly increased (P Ͻ 0.05). Similarly, none of these metabolites significantly differed among nondiabetic and diabetic HF patients except for alanine and isoleucine.
In contrast, shotgun MS/MS analyses revealed a global 22Ϫ79% increase in the 14 ACs assessed, reflecting a defect in mitochondrial FA ␤-oxidation (even chain number ACs) or branched-chain amino acid oxidation (C3 and C5-AC), referred thereafter as standard ACs, in HF patients compared with control subjects (Fig. 1A) . These include C2-AC and saturated ACs of various chain lengths plus two unsaturated ACs, C18:1-AC and C18:2-AC, which remained significantly increased in HF patients after adjusting for all covariates, including HOMA-IR and eGFR, except for short-chain C3 and C5, which were significantly different only after adjusting for age and sex. None of these ACs was significantly affected by diabetes except C2-AC, which was 78% higher in diabetic versus nondiabetic HF patients (Fig. 1B) .
Circulating ACs in HF Patients Are Strongly Associated With Disease-Related Factors
When PCA was first applied to measured clinical, biochemical, and metabolic parameters (53 variables total including the 14 ACs assessed by shotgun MS/MS analysis), the first component (PC1) fully discriminated HF patients from control subjects (Fig. 2) . The top two PCs accounted for 32.9% of the total variation (see Supplemental Excel Sheet S2 for loading scores). Although, as expected, NT-ProBNP (log) and urea, which are known disease severity proxies, strongly contributed to the separation between the two groups (loading score: Ϫ0.23), among the 18 variables with a loading score Ն│0.15│, 9 of them were ACs, including C2-AC (Ϫ0.24), MCACs (C14-AC and C12-AC: Ϫ0.19), and LCACs (C18:1-and C18-AC: Ϫ0.23 and C16-AC: Ϫ0.19). Subsequently, Pearson correlation was used to test for associations between various ACs and NT-ProBNP and urea, whose levels increase with disease severity, as well as total cholesterol, whose decrease level has been associated with negative outcomes and mortality in advanced HF (13) . The majority of these ACs showed a significant correlation with all these factors, which was positive for NT-ProBNP and urea but negative for total cholesterol (r ϭ Ϫ0.3, P Ͻ 0.05), in particular for C14-, C16-, C18-and C18-1-AC (Table 4) . Although renal dysfunction was reported to impact on blood AC accumulation (25) , none of the ACs except C6-carnitine correlated with eGFR (r ϭ Ϫ0.25, P Ͻ Shown in the Pearson correlation between saturated acylcarnitines of various chain lengths from C2 to C18 (including unsaturated species, specifically C18:1 and C18:2) and disease-related factors, namely, NH2-terminal pro-B-type natriuretic peptide (NT-ProBNP) and urea, as well as total cholesterol in heart failure patients. A Pearson coefficient (r) of Ͼ0 corresponds to a positive association, whereas an r value of Ͻ0 corresponds to a negative association. 0.047, data not shown), and we observed a negative correlation between HOMA-IR and MCACs (r ϭ Ϫ0.3, P Ͻ 0.05, data not shown). Finally, in addition, despite major changes in blood FAs in HF patients, as previously reported (6) , there was only a marginal correlation between these FAs and their corresponding ACs (data not shown).
Primary Cohort Subgroup Analyses Using LC-MS/MS Reveal Additional AC Species That Are Replicated in a Second Cohort
The analyses described above revealed that alterations in plasma ACs irrespective of chain length were a prominent feature of HF patients. Given the limitations of shotgun MS/MS to probe only few AC species arising principally from mitochondrial ␤-oxidation, we used a newly developed LC-MS/MS method to ascertain and extend our findings to additional ACs species, including unsaturated, OH-ACs, and DCACs, which could reflect perturbations in lipid metabolism beyond mitochondria and especially in peroxisomes. This method was first applied to a subgroup of subjects from the primary MHI cohort and then validated in a second cohort. It is noteworthy that the subgroup of subjects for the MHI cohort was selected to be comparable in number to the validation cohort.
Primary cohort. The subgroup of HF and control subjects were all men, which did not significantly differ for age, body mass index, eGFR, and HOMA-IR. HF patients were nondiabetic but had markedly depressed left ventricular ejection fraction (30.1 Ϯ 7.0%) and increased NT-ProBNP levels (P Ͻ 0.0001). Figure 3 shows results from LC-MS/MS analysis as a volcano plot, in which the most discriminant ACs among the 53 ACs tested (fold change Ͼ 1.3, FDR Ͻ 10%, corresponding to a P value Ͻ 0.038) are annotated (raw data are reported in Supplemental Excel Sheet S3). Although this subgroup of HF patients recapitulated a plasma profile for standard ACs similar to that of the entire cohort, there were, however, other ACs that have been poorly documented in human HF and were more discriminant, namely, 1) unsaturated ACs [C6:1-, C10:1#2-, C10:2-, C14:1-(#1; #2), and C18:3ACs], 2) OH-ACs [C8-OH-(#2; #3),C10-OH-, and C14-OH-ACs], and 3) DC-ACs [C6-DC-(#1;#2), C16-DC-, and C18-DC-ACs].
Validation cohort. Table 5 shows AC species measured by LC-MS/MS in CS and CV samples, which had an uncorrected P value Ͻ 0.05. Although the FDR was lower for CS versus CV samples (10% vs. 13%), we found no significant differences between AC species measured in these two types of samples in HF patients (cf. Supplemental Excel Sheet S4). Figure 4 shows the results as box plots for the most discriminant ACs in CS samples that were also similar to those reported for the primary subcohort (FDR ϭ 10%, corresponding to P Ͻ 0.044). These AC species include several standard LCACs such as C16-,C18:1-and C18:2-ACs or less usual ACs such as C16:1-, C18:3-, C20-, C20:1-, and C20:3-ACs (Fig. 4A) as well as some OH-ACs (C8-OH#2-and C12:1-OH#2-ACs; Fig.  4B ) and DC-ACs (C6-DC#1-C16-DC-and C18-DC-ACs; Fig.  4C ). Since the latter results pointed out to perturbations in peroxisomal FA metabolism, this notion was further substantiated by a more comprehensive lipid profiling of CS and CV samples using LC-QTOF, which enabled the detection of ACs with a chain length of Ͼ20 carbons, in contrast to the LC-triple quadrupole method, but also other classes of lipids, such as sphingolipids containing VLCFA, both of which were linked to impaired peroxisomal metabolism (51, 65) . Using the selected criteria (uncorrected P Ͻ 0.01, fold change Ͼ 1.3), 12 lipid species discriminated HF patients from control subjects in CS samples and 3 lipid species in CV samples. Table 6 shows the discriminating lipid species in CS samples. These include 1) three standard ACs (C-18:2, C18:2, and C18), as expected, but also a VLCAC, C26-AC, as well as 2) sphingolipids, either ceramide or sphingomyelin derivatives with fatty acyl side chains with 22Ϫ24 carbons, whose levels were, respectively, greater and lower in HF patients. The three lipid species in CV samples were similar to those reported for the CS samples, namely, sphingomyelins with FAs between 19 and 22 carbons.
DISCUSSION
In this study, various circulating energy-related metabolites were measured using MS-based methods in two cohorts consisting of optimally treated HF patients and control subjects to gain insights into the systemic metabolic perturbations in HF, particularly for FAs. Our HF patient population displayed typical clinical characteristics, including renal dysfunction (45) and insulin resistance (9), both of which can impact on many of the measured metabolites. Hence, all measured metabolites have been adjusted for these two potential confounding factors (eGFR and HOMA-IR) in addition to age and sex. Collectively, our results highlight major systemic metabolic alterations in HF patients, particularly for surrogates of FA metabolic dysfunction as recapitulated in Fig. 5 , which are independent of biological Fig. 3 . Volcano plot depicting LC-MS/MS-determined plasma acylcarnitine (AC) species statistically significant between heart failure (HF) patients and control subjects in the primary subcohort. Significance threshold [fold change Ͼ 1.3, false discovery rate ϭ 10%, corresponding to P Ͻ 0.038] was reached for 24 of 53 AC species profiled by LC-MS/MS in the primary subcohort (9 control subjects and 8 HF patients). The x-axis shows fold changes (log2) and the y-axis shows adjusted P values (Ϫlog10). Raw data used to generate the volcano plot are reported in Supplemental Excel Sheet S3. In the figure, Cx refers to the number of carbons in the acyl chain of carnitine derivatives. OH and DC indicate, respectively, hydroxylated ACs and dicarboxylic-ACs. Isomers of the same AC species, which structure remains to be elucidated, are indicated using numbers (e.g., AC #1/#2). traits and reflect a globally perturbed metabolic phenotype in these patients. Whereas shotgun MS/MS enabled the demonstration of a robust increase in standard ACs of various chain lengths, mostly saturated, reflecting mitochondrial dysfunction in FA ␤-oxidation, the use of LC-MS/MS methods revealed increases in circulating DC-and OH-ACs as well as in VLCFA derivatives, including C26-carnitine, reflecting dysregulated FA metabolism in other organelles beyond mitochondria, in particular peroxisomes.
HF Patients Exhibit Marginal Changes in Metabolites Reflecting Mitochondrial TCA Cycle and Redox State
Although mitochondrial dysfunction is being considered a hallmark of HF (57), except for citrate, other metabolites than ACs reflecting mitochondrial metabolism were only marginally affected in our optimally treated HF patients compared with control subjects. Moreover, the ␤-hydroxybutyrate-toacetate ratio and lactate-to-pyruvate ratio, surrogates of the mitochondrial or cytosolic NADH-to-NAD ϩ ratio (18), respectively, were similar to controls. This contrasts with increases in both of these ratios in inherited mitochondrial disease (60) . Unchanged mitochondrial redox status in HF patients suggests that globally the activity of the electron transport chain is not limiting despite alterations in the supply and metabolism of energy substrates. This notion concurs with some, albeit not all, literature data (17, 39) . For example, Holzem et al. (30) highlighted reduced FA use in isolated mitochondria from human failing hearts, which was attributed to impaired FA delivery rather than intrinsic mitochondrial dysfunction.
Shotgun MS/MS Shows Elevated AC Species Reflecting Dysregulation of Mitochondrial FA ␤-Oxidation in HF Patients
The application of the shotgun MS/MS method used for routine screening of inherited FA oxidation defects revealed, however, a global increase in circulating levels of many AC species in HF patients, consistent with dysregulated mitochondrial FA ␤-oxidation in human HF. These results, also obtained in the second cohort, concur but also extend those reported to date in a few cohorts of HF patients (2, 27, 36) . In this study, we show that increases in ACs occur independently of circulating FA changes and persist after adjustment for confounding variables such as age, sex, HOMA-IR, and eGFR and is similarly elevated in HF patients with or without diabetes. This contrasts with other LC-MS/MS was used to profile 53 acylcarnitines in plasma samples collected from the coronary sinus (8 heart failure patients and 8 control subjects) and central vein (10 heart failure patients and 8 control subjects) of the validation cohort. Data are expressed as mean fold changes in heart failure patients vs. control subjects. Shown are the acylcarnitines with an uncorrected P value of Ͻ0.05, corresponding to a false discovery rate of Ͻ0.10 (coronary sinus) and equal to 0.13 (central vein; not shown), using an unpaired t-test and Benjamini-Hochberg correction. Empty cells indicate that for the given acylcarnitine specie, significance (P value) was not reached.
circulating metabolites, such as the branched-chain amino acid isoleucine, found to be an early predictive marker of human T2D (71) and for which the difference between HF patients versus control subjects was lost after adjusting for HOMA-IR. The fact that ACs of all chain length (i.e., LCACs, MCACs, and SCACs) were elevated in plasma of HF patients indicate a global impairment of mitochondrial FA ␤-oxidation in one or many tissues, including the heart, which could result from defects or mismatch in activities of multiple enzymes and/or transporters involved in this pathway (47) . This includes possible alterations in enzymes catalyzing the conversion of acyl-CoA to ACs, namely carnitine palmitoyltransferase (CPT)-II for LCACs, carnitine-octanoyltransferase (CROT) for MCACs, and carnitine acetyltransferase (CRAT) for SCACs (66) or proteins involved in cellular AC efflux, namely, monocarboxylate transporter 9, SLC22 and SLC16 (solute carrier) (44) . Finally, elevated levels of C2-AC could also reflect a mismatch between acetyl-CoA formation, from both FA and glucose oxidation, and its utilization in the TCA cycle. It is noteworthy that changes in systemic ACs may also be associated with perturbations in glucose metabolism as it has been reported in muscle (58) or in the heart (42).
AC Species Reflecting Dysregulation of Mitochondrial ␤-Oxidation Are Strongly Associated With Markers of Disease Severity
Systemic metabolic perturbations are recognized as key contributors to the pathogenesis and progression of HF (21) . In this regard, circulating LCACs have been associated to adverse clinical outcomes in chronic HF (2) and reported to be predictors of cardiovascular mortality in incident dialysis patients (36) . There are many factors that are prevalent in HF patients and these could potentially explain elevated circulating ACs. First, ACs, particularly LCACs, have been linked to insulin resistance (54) as well as premature death and disability from heart disease (27) . Increased ACs can also occur as a result of renal dysfunction (25) , a prominent feature of HF patients. In this regard, the results from this study demonstrate that LCAC levels in HF patients remain significantly elevated after adjusting for HOMA-IR, concurring with the lack of correlation between plasma LCACs and insulin resistance in HF patients reported by Hunter et al. (33) but also after adjusting for eGFR. This suggests that elevated circulating LCAC levels occur independently of insulin resistance and kidney function. Our results also highlight associations between many individual Fig. 4 . Most discriminant LC-MS/MS-determined acylcarnitine (AC) species between heart failure (HF) patients and control subjects in the validation cohort. Significance threshold (false discovery rate ϭ 10%, corresponding to P Ͻ 0.044) was reached for 26 of 53 AC species profiled by LC-MS/MS in the coronary sinus of the validation cohort [8 control subjects (white) and 10 HF patients (gray)]. Results for most discriminant ACs that were also found in the primary subcohort, namely, long-chain ACs (LCACs; A), hydroxyl-AC (OH-ACs; B), and dicarboxylic ACs (DC-ACs; C), are depicted as box plots with rectangles displaying SD, the segment inside the median, and "whiskers" above and below the minimum and maximum. *P Ͻ 0.044; **P Ͻ 0.01.
ACs of various chain lengths from C2 to C18 with factors reflecting disease severity (NT-ProBNP and urea) or associated with negative outcomes or mortality (total cholesterol) in HF. Although it remains to be determined as to whether the elevated circulating levels of ACs are a cause or a consequence of HF and which tissue(s) contribute to these changes, it is nevertheless tempting to speculate that the association between ACs and NT-ProBNP could be related to the recently described role of natriuretic peptides in stimulating lipolysis from adipose tissue, a factor that could contribute to cachexia in the long term (16) . Irrespective of the underlying mechanisms responsible for the elevated circulating ACs, the latter may have adverse effects, particularly LCACs. These include 1) arrhythmias through modulation of several ionic currents, particularly increasing inward K ϩ current (23); 2) increasing intracellular Ca 2ϩ , thereby contributing to the activation of cell stress pathways relevant to apoptosis and cell death (44) ; and 3) activation of proinflammatory pathways (50) .
Extended Metabolic Profiling Using LC-MS/MS Highlights a Complex Phenotype of Impaired Lipid Metabolism in Mitochondria and Beyond in Peroxisomes
One unique finding of this study stems from the profiling of 53 ACs using LC-MS/MS, uncovering increases in other types of ACs, namely, DC-and OH-AC species. The identity of the majority of these measured ACs was validated using LC-QTOF, but chemical identity remains to be ascertained for some isomeric species such as C4-OH-AC versus C3-DC-AC. Recently, C4-OH-AC was shown to be increased in a mouse model of HF as well as in human HF, reflecting higher oxidation rates of ketone bodies, whose levels were also elevated in this study model (7, 10) . OH-ACs species are commonly used as markers of defects in the mitochondrial ␤-oxidation enzymes MC and/or LC 3-hydroxyacyl-CoA dehydrogenase (HAD), and patients carrying mutations in the LCHAD gene depict muscle weakness and cardiomyopathy (47) . OH-ACs could, however, also be formed through -oxidation initiated by cytochrome P-450 (CYP450) enzymes, which occurs in the microsomal compartment or smooth endoplasmic reticulum (28) . Indeed, one unique finding of this study is the elevated levels of plasma DC-ACs in HF patients, particularly C16-DC-and C18-DC-ACs, which are markers of inherited defects of peroxisome biogenesis (48) . We also observed a significant accumulation of C6-DC-AC; C6-and C8-DCs are considered to be end products of peroxisomal ␤-oxidation of LC-DCAs (32) . This notion of a perturbed peroxisomal FA metabolism in HF is further supported by our finding of changes in CS samples in C26-carnitine (elevated), a recently identified biomarker of X-linked adrenoleukodystrophy, a peroxisomal disease (65) , and in lipid species enriched in fatty acyl side chains containing Ͼ20 carbons (lowered) (70) .
The clinical significance of increased OH-or DC-ACs as well as the impact of peroxysomal FA metabolism in HF remains, however, to be further explored. Clearly, peroxisomes are intimately connected to mitochondria for maintaining lipid metabolism homeostasis (70) . They also share similar regulation for, e.g., peroxisome proliferator-activated receptor (PPAR)-␣ signaling (55) , which is depressed in human and experimental HF models (8) . After a few cycles of ␤-oxidation, peroxisomes can provide FAs of shorter chain length to the mitochondria for further ␤-oxidation. In contrast to mitochondria, ␤-oxidation in peroxisomes is, however, not linked to energy metabolism. Increased OH-FAs were also shown to uncouple oxidative phosphorylation in heart mitochondria, which could potentially further impair energy homeostasis (61) . Interestingly, a recent metabolomics quantitative trait loci study in the CATHGEN cohort highlighted a strong association between SC-DCAs (including C6-DCA) and gene variants predictive of cardiovascular disease and involved in endoplasmic reticulum regulation (37) . Furthermore, mice lacking specific peroxisomal proteins (peroxines) show cardiac metabolic and mitochondrial remodeling as well as contractile dysfunction (15) . Finally, recent findings have highlighted a compensatory role of peroxisomes when mitochondria are dysfunctional (67), as it occurs in ischemic hearts (40) . Taken together, these literature evidences provide additional impetus to further investigate the significance of our finding of a systemic metabolic signature reflecting perturbations in peroxisomal FA metabolism in human HF.
Study Limitations
Given the exploratory nature of this study, a number of issues should be taken into consideration in data interpretation. First, there are other potential confounding factors beyond age, sex, insulin resistance, and kidney function that are inherent to the HF condition and unavoidable but could nevertheless contribute to the observed changes in the plasma AC profile of HF patients with reduced ejection fraction. These include medications known to affect cellular FA metabolism or AC release (4), such as 1) lipid-lowering agents, e.g., statin, which increase carnitine acetyltransferase activity (11) and fibrates, which promote CYP450 and peroxisomal proliferation through PPAR-␣ induction (55, 69) ; or 2) ␤-blockers that decrease CPT-I activity and decrease OCTN2 expression (46) . For the latter, we found no significant differences in the plasma level LC-MS/MS was used to identify additional lipid features that segregate heart failure patients from control subjects in samples collected from the coronary sinus (8 heart failure patients and 8 control subjects) and central vein (10 heart failure patients and 8 control subjects) of the validation cohort. Features, defined by mass and retention time, were selected based on the following criteria: P value Ͻ 0.01 (unpaired t-test) and absolute fold change Ͼ 1.3. Selected features were annotated using the METLIN database and identified using MS/MS. Cer, ceramide; LPC, lysophosphatidylcholine; SM, sphyngomyelin. *MS/MS fragmentation pattern did not provide sufficient information to identify the fatty acyl chains.
of ACs, irrespective of chain length between HF patients from the primary cohort without or with ␤-blockers (data not shown). Second, plasma ACs reflect the contribution of many organs or tissues (53) that cannot be distinguished using the present study design. Although altered FA oxidation has been documented in failing hearts in animal models and humans (1, 39) , HF is known to result in multiple organ dysfunctions beyond the heart, including muscle and the liver (29, 38) . Our finding of correlations between circulating ACs and NTproBNP and total cholesterol suggest at least a contribution of the heart and liver, respectively. Direct evidence for this would, however, require measurements of arteriovenous differences in ACs. Third, and unfortunately, our study was limited to one time point, thereby limiting our capacity to infer on the clinical significance of increased AC species in HF. Our second cohort had also a very small sample size. Future studies should include larger cohorts of HF patients and a prospective and longitudinal study design with a followup of cardiac events such as atrial fibrillation or arrhythmia to examine the potential of ACs to serve as biomarkers of adverse cardiac events and or as target for therapeutic interventions.
Conclusions
Taking advantage of various MS methods to profile energyrelated metabolites, this study demonstrated that symptomatic, optimally treated HF patients display a global elevation in various circulating AC species, irrespective of age, sex, insulin resistance, and renal dysfunction. These ACs include LCACs, OH-ACs, DC-ACs, and VLCACs, such as C26-AC. Collectively, the results from this study highlight multiple perturbation sites in FA metabolism, particularly in their oxidation, in mitochondria, but also beyond, namely, in the peroxisome. Additional studies are needed to clarify mechanisms and factors governing the accumulation of individual AC species and the main contributing organs as well as to evaluate their Fig. 5 . Proposed pathways for intracellular acylcarnitine (AC) formation from fatty acid (FA) metabolism in mitochondria versus other organelles. The scheme depicts proposed FA metabolic pathways in mitochondria, peroxisomes, and the endoplasmic reticulum (ER) from which the various AC species that were shown to be increased in heart failure patients in this study (indicated by a northeastward-facing arrows) can be formed from their corresponding acyl-CoA counterparts. This could occur in one or many tissues, such as the heart, muscle, or liver, through the following potential mechanisms. potential value as prognostic circulating markers of adverse events in HF patients, including those with reduced or preserved ejection fraction, given the increasing prevalence of the latter group in women and with aging. Nevertheless, the respective role of peroxisomes and the endoplasmic reticulum in HF pathogenesis having being relatively unexplored to date, this study opens an attractive and novel avenue for basic and clinical research in this field.
